Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix to Repurchase $95.5M of Senior Notes as Part of Settlement

NEW YORK (GenomeWeb News) – Affymetrix has settled a legal dispute with holders of the company's 3.50 percent senior notes, and as part of the settlement it has agreed to start within two weeks a tender offer to repurchase the entire $95.5 million aggregate principal amount of the notes currently outstanding plus accrued interest, it said in a document filed with the US Securities and Exchange Commission.

Tang Capital Partners, owners of about $78.3 million principal amount of the notes, has agreed to tender all of its notes in the offer, Affy said.

In addition, Affy said that based on discussions with lenders who have said they will finance the firm's pending acquisition of eBioscience, it expects it will need to restructure the financing arrangements in order to complete the deal. The company has not reached any agreements or understanding with its lenders or other financing sources, it said.

The settlement pertains to a class action lawsuit brought against Affy by Tang Capital in December in the Superior Court of California, County of Santa Clara. The lawsuit alleged Affy's bid for eBioscience constituted a fundamental change under the indenture that governs the notes due in 2038.

Affy announced its $330 million bid for eBioscience in late November but has pushed back the completion date twice since then. It now expects to complete the deal by the end of the first quarter.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.